MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock in public...
$93,787K
Proceeds from option
exercises
$28K
Net cash provided by
(used in) financing...
$93,815K
Net increase
(decrease) in cash, cash...
$75,103K
Canceled cashflow
$18,712K
Accounts payable
$1,698K
Non-cash stock
compensation expense
$1,452K
Accretion of debt discount
$306K
Depreciation expense
$149K
Non-cash lease expense
$92K
Non-cash interest
expense
$39K
Net cash used in
operating activities
-$18,037K
Net cash used in
investing activities
-$675K
Canceled cashflow
$3,736K
Net income (loss)
-$8,861K
Change in fair value of
warrant liabilities
-$7,643K
Accrued expenses
-$3,858K
Purchase of fixed assets
$675K
Prepaid expenses and
other current assets
$1,260K
Lease liability
-$108K
Deferred income
-$22K
Other assets
$21K
Back
Back
Cash Flow
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL)
source: myfinsight.com